Literature DB >> 35937648

Toward Ending the HIV Epidemic: Temporal Trends and Disparities in Early ART Initiation and Early Viral Suppression Among People Newly Entering HIV Care in the United States, 2012-2018.

Jun Li1, Elizabeth Humes2, Jennifer S Lee2, Keri N Althoff2, Jonathan A Colasanti3, Ronald J Bosch4, Michael Horberg5, Peter F Rebeiro6, Michael J Silverberg7, Ank E Nijhawan8, Angela Parcesepe9, John Gill10, Sarita Shah11, Heidi Crane12, Richard Moore13, Raynell Lang2, Jennifer Thorne13, Timothy Sterling14, David B Hanna15, Kate Buchacz1.   

Abstract

Background: In 2012, the US Department of Health and Human Services updated their HIV treatment guidelines to recommend antiretroviral therapy (ART) for all people with HIV (PWH) regardless of CD4 count. We investigated recent trends and disparities in early receipt of ART prescription and subsequent viral suppression (VS).
Methods: We examined data from ART-naïve PWH newly presenting to HIV care at 13 North American AIDS Cohort Collaboration on Research and Design clinical cohorts in the United States during 2012-2018. We calculated the cumulative incidence of early ART (within 30 days of entry into care) and early VS (within 6 months of ART initiation) using the Kaplan-Meier survival function. Discrete time-to-event models were fit to estimate unadjusted and adjusted associations of early ART and VS with sociodemographic and clinical factors.
Results: Among 11 853 eligible ART-naïve PWH, the cumulative incidence of early ART increased from 42% in 2012 to 82% in 2018. The cumulative incidence of early VS among the 8613 PWH who initiated ART increased from 83% in 2012 to 93% in 2018. In multivariable models, factors independently associated with delayed ART and VS included non-Hispanic/Latino Black race, residence in the South census region, being a male with injection drug use acquisition risk, and history of substance use disorder (SUD; all P ≤ .05). Conclusions: Early ART initiation and VS have substantially improved in the United States since the release of universal treatment guidelines. Disparities by factors related to social determinants of health and SUD demand focused attention on and services for some subpopulations. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022.

Entities:  

Keywords:  ART initiation; Ending the HIV Epidemic Initiative; epidemiology; health disparity; viral suppression

Year:  2022        PMID: 35937648      PMCID: PMC9348610          DOI: 10.1093/ofid/ofac336

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   4.423


  27 in total

1.  Trends in Racial and Ethnic Disparities in Antiretroviral Therapy Prescription and Viral Suppression in the United States, 2009-2013.

Authors:  Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-01       Impact factor: 3.731

2.  Ending the HIV Epidemic: A Plan for the United States.

Authors:  Anthony S Fauci; Robert R Redfield; George Sigounas; Michael D Weahkee; Brett P Giroir
Journal:  JAMA       Date:  2019-03-05       Impact factor: 56.272

3.  Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation.

Authors:  Jennifer S Lee; Stephen R Cole; David B Richardson; Dirk P Dittmer; William C Miller; Richard D Moore; Mari Kitahata; Christopher Mathews; Kenneth Mayer; Elvin Geng; Chad J Achenbach; Joseph J Eron
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

4.  Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.

Authors:  Richard M Novak; Rachel L D Hart; Joan S Chmiel; John T Brooks; Kate Buchacz
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

5.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

Authors:  R Detels; A Muñoz; G McFarlane; L A Kingsley; J B Margolick; J Giorgi; L K Schrager; J P Phair
Journal:  JAMA       Date:  1998-11-04       Impact factor: 56.272

6.  Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada.

Authors:  Peter F Rebeiro; Alison G Abraham; Michael A Horberg; Keri N Althoff; Baligh R Yehia; Kate Buchacz; Bryan M Lau; Timothy R Sterling; Stephen J Gange
Journal:  AIDS Patient Care STDS       Date:  2017-02-27       Impact factor: 5.078

7.  Barriers to HIV Care by Viral Suppression Status Among US Adults With HIV: Findings From the Centers for Disease Control and Prevention Medical Monitoring Project.

Authors:  Sharoda Dasgupta; Yunfeng Tie; Linda Beer; Jennifer Fagan; John Weiser
Journal:  J Assoc Nurses AIDS Care       Date:  2021 Sep-Oct 01       Impact factor: 1.354

8.  The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada.

Authors:  Jielin Zhu; Ignacio Rozada; Jummy David; David M Moore; Silvia A Guillemi; Rolando Barrios; Julio S G Montaner; Viviane D Lima
Journal:  EClinicalMedicine       Date:  2019-07-10

9.  Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system.

Authors:  Ann N Do; Eli S Rosenberg; Patrick S Sullivan; Linda Beer; Tara W Strine; Jeffrey D Schulden; Jennifer L Fagan; Mark S Freedman; Jacek Skarbinski
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

10.  Understanding Cross-Sectional Racial, Ethnic, and Gender Disparities in Antiretroviral Use and Viral Suppression Among HIV Patients in the United States.

Authors:  Linda Beer; Christine L Mattson; Heather Bradley; Jacek Skarbinski
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.